Advertisement

Topics

Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting 2018

08:04 EST 9 Nov 2018 | FinanzNachrichten

-- Phase 2 Data Presented on Investigational FXR Agonist GS-9674 in NASH -- -- Enrollment Complete in Phase 2 ATLAS Combination Trial of Three Investigational Therapies Targeting Distinct Mechanis...

Original Article: Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting 2018

NEXT ARTICLE

More From BioPortfolio on "Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting 2018"

Advertisement
Quick Search
Advertisement
Advertisement